PET Identifies Inflammation in Fibromyalgia Patients
By MedImaging International staff writers Posted on 09 Oct 2018 |
Image: PET image highlights increased glial activation in FM patients with fibromyalgia (Photo courtesy of Marco Loggia/ MGH).
Positron emission tomography (PET) can highlight areas of increased glial activation in the brain of patients with fibromyalgia (FM), claims a new study.
Researchers at Massachusetts General Hospital (MGH; Boston, USA) and the Karolinska Institutet (KI; Solna, Sweden) conducted a PET study using a tracer that binds to the translocator protein (TSPO), which is upregulated in activated microglia and astrocytes. The study included 31 FM patients and 27 healthy controls examined using PET. Standardized uptake values were normalized by occipital cortex signal (SUVR) and distribution volume (VT), as computed from the tracer data. PET imaging metrics were compared across groups, and when differing across groups, against clinical variables.
The results revealed that FM patients demonstrated widespread cortical elevations, and no decreases, which was most pronounced in the medial and lateral walls of the frontal and parietal lobes. The elevations in the tracer and SUVR were correlated both spatially, and, in several areas, also in terms of magnitude. In addition, higher subjective ratings of fatigue in FM patients were associated with higher tracer SUVR in the anterior and posterior middle cingulate cortices. The study was published on September 14, 2018, in Brain, Behavior and Immunity.
“We don’t have good treatment options for fibromyalgia, so identifying a potential treatment target could lead to the development of innovative, more effective therapies,” said senior author Marco Loggia, PhD, of the MGH Martinos Center for Biomedical Imaging. “Finding objective neurochemical changes in the brains of patients with fibromyalgia should help reduce the persistent stigma that many patients face, often being told their symptoms are imaginary and there’s nothing really wrong with them.”
Fibromyalgia is characterized by such symptoms as chronic widespread pain, sleep problems, fatigue, and problems with thinking and memory; the cause is unknown. Fibromyalgia affects around seven times as many women as men, and typically develops between the ages of 30 and 50, but can occur in people of any age, including children and the elderly. Some estimates suggest nearly 1 in 20 people may be affected by fibromyalgia to some degree.
Related Links:
Massachusetts General Hospital
Karolinska Institutet
Researchers at Massachusetts General Hospital (MGH; Boston, USA) and the Karolinska Institutet (KI; Solna, Sweden) conducted a PET study using a tracer that binds to the translocator protein (TSPO), which is upregulated in activated microglia and astrocytes. The study included 31 FM patients and 27 healthy controls examined using PET. Standardized uptake values were normalized by occipital cortex signal (SUVR) and distribution volume (VT), as computed from the tracer data. PET imaging metrics were compared across groups, and when differing across groups, against clinical variables.
The results revealed that FM patients demonstrated widespread cortical elevations, and no decreases, which was most pronounced in the medial and lateral walls of the frontal and parietal lobes. The elevations in the tracer and SUVR were correlated both spatially, and, in several areas, also in terms of magnitude. In addition, higher subjective ratings of fatigue in FM patients were associated with higher tracer SUVR in the anterior and posterior middle cingulate cortices. The study was published on September 14, 2018, in Brain, Behavior and Immunity.
“We don’t have good treatment options for fibromyalgia, so identifying a potential treatment target could lead to the development of innovative, more effective therapies,” said senior author Marco Loggia, PhD, of the MGH Martinos Center for Biomedical Imaging. “Finding objective neurochemical changes in the brains of patients with fibromyalgia should help reduce the persistent stigma that many patients face, often being told their symptoms are imaginary and there’s nothing really wrong with them.”
Fibromyalgia is characterized by such symptoms as chronic widespread pain, sleep problems, fatigue, and problems with thinking and memory; the cause is unknown. Fibromyalgia affects around seven times as many women as men, and typically develops between the ages of 30 and 50, but can occur in people of any age, including children and the elderly. Some estimates suggest nearly 1 in 20 people may be affected by fibromyalgia to some degree.
Related Links:
Massachusetts General Hospital
Karolinska Institutet
Latest General/Advanced Imaging News
- PET Scans Reveal Hidden Inflammation in Multiple Sclerosis Patients
- Artificial Intelligence Evaluates Cardiovascular Risk from CT Scans
- New AI Method Captures Uncertainty in Medical Images
- CT Coronary Angiography Reduces Need for Invasive Tests to Diagnose Coronary Artery Disease
- Novel Blood Test Could Reduce Need for PET Imaging of Patients with Alzheimer’s
- CT-Based Deep Learning Algorithm Accurately Differentiates Benign From Malignant Vertebral Fractures
- Minimally Invasive Procedure Could Help Patients Avoid Thyroid Surgery
- Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery
- AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning
- Imaging Technology Provides Ground-Breaking New Approach for Diagnosing and Treating Bowel Cancer
- CT Coronary Calcium Scoring Predicts Heart Attacks and Strokes
- AI Model Detects 90% of Lymphatic Cancer Cases from PET and CT Images
- Breakthrough Technology Revolutionizes Breast Imaging
- State-Of-The-Art System Enhances Accuracy of Image-Guided Diagnostic and Interventional Procedures
- Catheter-Based Device with New Cardiovascular Imaging Approach Offers Unprecedented View of Dangerous Plaques
- AI Model Draws Maps to Accurately Identify Tumors and Diseases in Medical Images